中文名稱：維多珠單抗

中文同義詞：維多珠單抗

英文名稱：Vedolizumab

英文同義詞：Vedolizumab

產(chǎn)品描述

維多珠單抗類似物是一種整合素受體拮抗劑，是一種與人α4β7整合素結(jié)合的人源化IgG1單克隆抗體，分子量約147kDa，由中國倉鼠卵巢細(xì)胞生產(chǎn)。

性質(zhì)

Name


Biosimilar of Vedolizumab

CAS NO.


943609-66-3

Type


Whole antibody

Source


Humanized

Target


Integrin α4β7

Clone


Monoclone

Molecular Weight


147 kDa

Formula


C6528H10072N1732O2042S42

Antibody Form


Purified immunoglobulin

Physical Form


Solution

Grade Standard


Medicine Grade

Storage


-70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.

生物活性

Vedolizumab是一種全人源化單克隆抗體，特異性拮抗α4β7整合素，抑制α4β7整合素對腸道黏膜細(xì)胞粘附分子MAdCAM-1的結(jié)合。Vedolizumab blocks the α4β7 integrin, results in gut-selective anti-inflammatory activity. Vedolizumab binds to memory CD4(+) T and B lymphocytes with subnanomolar potency (EC(50) = 0.3-0.4 nM). Vedolizumab also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels. Vedolizumab selectively inhibits adhesion of alpha(4)beta(7)-expressing cells to mucosal addressin cell adhesion molecule 1 (median inhibition concentration [IC(50)] = 0.02-0.06 microg/ml) and fibronectin (IC(50) = 0.02 microg/ml), but not vascular cell adhesion molecule 1.
不同實驗動物依據(jù)體表面積的等效劑量轉(zhuǎn)換表（數(shù)據(jù)來源于FDA指南）

小鼠 大鼠 兔 豚鼠 倉鼠 狗
重量 (kg) 0.02 0.15 1.8 0.4 0.08 10
體表面積 (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km 系數(shù) 3 6 12 8 5 20
動物 A (mg/kg) = 動物 B (mg/kg) × 動物 B的Km系數(shù)
動物 A的Km系數(shù)

例如，依據(jù)體表面積折算法，將白藜蘆醇用于小鼠的劑量22.4 mg/kg 換算成大鼠的劑量，需要將22.4 mg/kg 乘以小鼠的Km系數(shù)（3），再除以大鼠的Km系數(shù)（6），得到白藜蘆醇用于大鼠的等效劑量為11.2 mg/kg。
儲備液配制

以下數(shù)據(jù)基于產(chǎn)品分子量，對于特殊產(chǎn)品，請參照COA中的儲備液配制條件和說明進(jìn)行操作。
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 0.0068 mL 0.0341 mL 0.0681 mL
5 mM 0.0014 mL 0.0068 mL 0.0136 mL
10 mM 0.0007 mL 0.0034 mL 0.0068 mL
參考文獻(xiàn)

Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.
Fedyk ER, et al. Inflamm Bowel Dis. 2012 Nov;18(11):2107-19. PMID: 22419649.

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
Soler D, et al. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. PMID: 19509315.

單抗藥物對照品
貝伐單抗，Bevacizumab 納武單抗，Nivolumab
帕妥珠單抗，Pertuzumab 曲妥珠單抗，Trastuzumab
阿達(dá)木單抗，Adalimumab 帕姆單抗，Pembrolizumab
迪諾蘇單抗，Denosumab 阿替唑單抗，Atezolizumab
優(yōu)特克諾單抗，Ustekinumab 維多珠單抗，Vedolizumab
1、33個產(chǎn)品，三種規(guī)格：1mg，2mg，5mg；
2、價格優(yōu)，全現(xiàn)貨；
3、科研產(chǎn)品，僅用科研，禁用臨床；

Supplier供應(yīng)商：BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心
電話：010-53513060
網(wǎng)址http://www.biovector.net